Swiss National Bank Increases Investment in Aurinia Pharmaceuticals

🌥️Trending News

The Swiss National Bank has recently increased its stock portfolio with Aurinia Pharmaceuticals ($NASDAQ:AUPH) Inc., a publicly traded biopharmaceutical company based in Canada. The company is currently in a late-stage clinical trial for its lead product candidate, Voclosporin, which is a novel therapeutic to treat lupus nephritis. Aurinia has been highly successful so far, with its stock price increasing five-fold this year alone. This has prompted the Swiss National Bank to invest in the company and add it to its portfolio of stocks.

Moreover, Aurinia Pharmaceuticals is also actively pursuing partnerships with other leading biopharmaceutical companies to further advance its drug development pipeline. The increased investment from the Swiss National Bank is a signal of confidence in the potential of Aurinia Pharmaceuticals and its ability to bring new treatments to patients in need. As the company’s lead product candidate continues to move closer to regulatory approval, Aurinia will undoubtedly become an even more attractive investment opportunity.

Stock Price

The Swiss National Bank (SNB) has recently increased its investment in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). On Monday, AURINIA PHARMACEUTICALS stock opened at $9.0 and closed the day at $8.8, representing a 2.6% drop from its prior closing price of $9.1. The share price decline, however, did not deter SNB from raising its stake in the company. Consequently, SNB is now the second-largest institutional shareholder of Aurinia Pharmaceuticals, after FMR LLC. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…

Analysis

Upon analyzing AURINIA PHARMACEUTICALS‘s fundamentals, GoodWhale has classified the company as a ‘cheetah’ based on its Star Chart. This type of company has achieved high revenue or earnings growth, yet is considered less stable due to lower profitability. Given this assessment, investors who are looking for short-term gains could be interested in investing in AURINIA PHARMACEUTICALS. However, GoodWhale gives AURINIA PHARMACEUTICALS a low health score of 3/10 due to its cashflows and debt. This suggests that the company is less likely to sustain future operations in times of crisis. In terms of strengths and weaknesses, AURINIA PHARMACEUTICALS is strong in asset and growth, but weak in dividend and profitability. Therefore, investors should conduct further research before investing. More…

Peers

The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.

– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)

Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.

– Vaxart Inc ($NASDAQ:VXRT)

Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.

– MediWound Ltd ($NASDAQ:MDWD)

MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.

Summary

The Swiss National Bank has recently increased its stock holdings in Aurinia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. The bank’s decision to invest in the company is a sign of the potential that Aurinia holds, as investors seek to benefit from the innovative drugs and treatments it is researching and developing.

In addition, Aurinia’s commitment to expanding its operations and launching new products into larger markets suggests that this investment could be highly profitable over the long run. Furthermore, investors should consider the company’s financial performance and its track record of success when determining whether or not to invest in the company. With the potential for significant returns and a strong financial standing, Aurinia Pharmaceuticals Inc. is an attractive option for investors who are looking for a long-term investment opportunity.